Similar Efficacy, Safety, and Immunogenicity of the Biosimilar BI 695501 and Adalimumab Reference Product in Patients with Moderate-to-severe Chronic Plaque Psoriasis: Results from the Randomized Phase III VOLTAIRE-PSO Study.
Expert opinion on biological therapy（2020）
关键词
Adalimumab,BI 695501,biosimilar,equivalence,psoriasis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要